A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis

por Edwards, Christopher J., Sawant, Ruta, Garg, Vishvas, Du, Ella X., Friedman, Alan, Betts, Keith A.
Publicado 2020

Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis

por Pope, Janet, Sawant, Ruta, Tundia, Namita, Du, Ella X., Qi, Cynthia Z., Song, Yan, Tang, Patrick, Betts, Keith A.
Publicado 2020

Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis

por Pope, Janet, Sawant, Ruta, Tundia, Namita, Du, Ella X., Qi, Cynthia Z., Song, Yan, Tang, Patrick, Betts, Keith A.
Publicado 2021

Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data

por Freeman, Morganna, Betts, Keith A., Jiang, Shan, Du, Ella X., Gupte-Singh, Komal, Lu, Yichen, Rao, Sumati, Shoushtari, Alexander N.
Publicado 2019

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A

por Pocoski, Jennifer, Li, Nanxin, Ayyagari, Rajeev, Church, Nikki, Maas Enriquez, Monika, Xiang, Quer, Kelkar, Sneha, Du, Ella X, Wu, Eric Q, Xie, Jipan
Publicado 2016

Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis...

por Weber, Jeffrey S., Poretta, Tayla, Stwalley, Brian D., Sakkal, Leon A., Du, Ella X., Wang, Travis, Chen, Yan, Wang, Yan, Betts, Keith A., Shoushtari, Alexander N.
Publicado 2022

Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence...

por Weber, Jeffrey S., Poretta, Tayla, Stwalley, Brian D., Sakkal, Leon A., Du, Ella X., Wang, Travis, Chen, Yan, Wang, Yan, Betts, Keith A., Shoushtari, Alexander N.
Publicado 2022

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma

por Geynisman, Daniel M., Burotto, Mauricio, Porta, Camillo, Suarez, Cristina, Bourlon, Maria T., Huo, Stephen, Del Tejo, Viviana, Du, Ella X., Yang, Xiaoran, Betts, Keith A., Choueiri, Toni K., McGregor, Bradley
Publicado 2022

Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma

por McGregor, Bradley, Geynisman, Daniel M, Burotto, Mauricio, Porta, Camillo, Suarez, Cristina, Bourlon, Maria T, Del Tejo, Viviana, Du, Ella X, Yang, Xiaoran, Sendhil, Selvam R, Betts, Keith A, Huo, Stephen
Publicado 2023